Mesoporous silica nanoparticles with lactose-mediated targeting effect to deliver platinum(IV) prodrug for liver cancer therapy
Mesoporous silica nanoparticles with lactose-mediated targeting effect to deliver platinum(IV) prodrug for liver cancer therapy
复制标题
介孔二氧化硅纳米粒子具有乳糖介导的靶向作用，可递送铂（IV）前药用于肝癌治疗
DOI：
10.1039/c7tb01704a
复制
发表时间：
2017
影响因子：
7
通讯作者：
Huang Yubin
中科院分区：
文献类型：
--
作者：
Wang Zigui;Wu Peng;He Zhilong;He Hongyan;Rong Weifeng;Li Jizhen;Zhou Dongfang;Huang Yubin
化疗是治疗不能切除的肝细胞癌最常用的治疗策略。然而，化疗药物的低递送效率和对健康组织的严重毒性限制了治疗功效。为了应对这些挑战，首次开发了结合铂（IV）前药的活性靶向介孔二氧化硅纳米颗粒作为肝癌的治疗方法。利用肝靶向乳糖酸（LA）的优势，智能纳米载体不仅延长了循环时间，而且有效地集中在肝脏肿瘤部位。此外，结合的铂（IV）可以在还原性肿瘤环境中被还原，以快速释放活性铂（II）。这种新型的靶向自响应载药系统为肝癌化疗提供了新的前景。
Chemotherapy is the most common therapeutic strategy for the treatment of unresectable hepatocellular carcinoma. However, the therapeutic efficacy is limited by the low delivery efficiency of chemotherapeutics and severe toxicity towards healthy tissues. To address these challenges, active-targeting mesoporous silica nanoparticles conjugating a platinum(IV) prodrug were developed as a therapy for liver cancer for the first time. Taking advantage of liver-targeting lactobionic acid (LA), the smart nano-carriers not only enhanced the circulation time, but also effectively concentrated at the liver tumor site. Moreover, the conjugated platinum(IV) could be reduced in the reductive tumor environment for the fast release of active platinum(II). The novel targeting and self-responsive drug-loading system offers new prospects for liver cancer chemotherapy.